Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/25/2008
 
First Published:
2/17/2006
1.
Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
NCI-06-C-0041
7542, NCI-7542, NCI-P6702, NCT00295958
Last Modified:
12/20/2007
2.
Phase I Study of the Recombinant Immunotoxin LMB-2 in Patients With Tac-Expressing Leukemias and Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
NCI-96-C-0064F
NCI-T95-0042N, T95-0042, NCT00002765
Last Modified:
5/31/2007
 
First Published:
5/28/2004
3.
Phase I Study of LMB-2 Immunotoxin in Pediatric Patients With CD25-Positive Relapsed or Refractory Leukemia or Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
6 months to 21 years
NCI
NCI-04-C-0168
NCI-5903, 5903, NCT00085150
Last Modified:
6/9/2008
 
First Published:
10/14/2006
4.
Pilot Study of Fludarabine Phosphate and Cyclophosphamide Followed By LMB-2 Immunotoxin in Patients With CD25-Positive Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Biomarker/Laboratory analysis, Treatment
Completed
18 and over
NCI
NCI-06-C-0240
NCI-P6761, 7835, NCI-7835, NCT00389506
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute